Phase 4 Study to Assess the Safety of Trastuzumab Deruxtecan, in Indian Patients
Status:
RECRUITING
Trial end date:
2026-10-31
Target enrollment:
Participant gender:
Summary
A PROSPECTIVE, MULTI-CENTER, PHASE 4, SINGLE ARM STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN